International peptide-drug launches in 2026 are reshaping access far faster than the US market. Novo Nordisk Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC on May 18, 2026 the company is going 'all in' on launching the Wegovy pill outside the US, with the UK, Germany, and Denmark at the front of the queue. Cumulative US Wegovy pill prescriptions crossed 2 million in the 18 weeks since the January 5, 2026 launch — the data point Novo is using to justify the international push.
The generic-semaglutide rollout cycle is moving in parallel. India's composition patent lapsed March 20, 2026, triggering 26+ branded generics from 13 companies at prices as low as $14 per month. Canada became the first G7 country with approved generics on April 28 (Dr. Reddy's) and May 1 (Apotex), with Sandoz targeting Q3 2026 commercial launch. Brazil, China, Turkey, and seven other countries cover 40% of the global population and 48% of the global obesity burden with patent timing through 2026 or 2027.
Stories here cover commercial launches, regulatory approvals across non-US markets, and the pricing and access dynamics that follow patent expiry. See #wegovy-pill, #generic-semaglutide, and #novo-nordisk.
Novo Nordisk launched the Wegovy pill in the United Arab Emirates on June 3, the first country outside the US to make the oral semaglutide tablet available since the January 5 US launch. The UAE rollout used a distribution structure that piggybacks on existing diabetes-channel infrastructure rather than a parallel direct-to-consumer build, and arrived ahead of the UK MHRA approval today. Novo had previously guided to second-half 2026 for international rollouts.
A June 7 Novo Nordisk announcement, timed to ADA 2026, said the Wegovy pill (oral semaglutide 25 mg) had surpassed 3 million US prescriptions since its January 5 launch, with one prescription filled roughly every five seconds. The first million took 12 weeks (to March 23); the next 2 million came in 10 weeks. More than 80% of new Wegovy pill scripts go to patients new to GLP-1 therapy, suggesting market expansion rather than brand switching, and the first international launches outside the US are set for the second half of 2026.
Novo Nordisk announced on May 22 that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency adopted a positive opinion recommending marketing authorization of Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The recommendation includes data from SELECT in the label — the cardiovascular outcomes trial that documented a 20% major adverse cardiovascular event reduction with injectable Wegovy. The CHMP opinion is the first oral GLP-1 EU approval recommendation for weight management. OASIS 4 Phase 3 data anchoring the filing: 16.6% mean weight loss in adults with obesity or overweight plus one comorbidity, comparable to injectable Wegovy 2.4 mg. Novo plans to launch the pill in select non-US markets in H2 2026, with UK, Germany, and Denmark previously flagged as the first international launches (CNBC May 18). The CHMP opinion confirms the international expansion path Novo's EVP Larsen described.
Novo Nordisk's Executive Vice President for International Operations Emil Kongshøj Larsen told CNBC May 18 the company is preparing to go 'all in' on launching its Wegovy pill outside the US, with UK, Germany, and Denmark at the front of the international queue. The company disclosed cumulative US Wegovy pill prescriptions have crossed 2 million in the 18 weeks since the January 5 launch — roughly double the >1M figure CEO Maziar Doustdar shared on May 14. Larsen's quote: 'When we launch, we'll go all in.' The international expansion lands as Novo's full-year 2026 guidance still calls for revenue and profit declines between 4% and 12%, but the company hiked guidance slightly last week after Q1 oral semaglutide sales beat expectations. The international Wegovy pill timing matters for Lilly's Foundayo (orforglipron), which had its US PBM coverage activate mid-May but has no near-term international launch date.
Novo Nordisk Q1 management commentary delivered alongside the ECO 2026 data updates confirmed that the Wegovy pill (oral semaglutide 25 mg) will launch in select international markets in the second half of 2026 with European approval expected before year-end. The international rollout follows the January 5 US launch that delivered DKK 2.26B (~$354M) in Q1 sales — nearly double the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and >2M cumulative US prescriptions. Wegovy now holds 65% of all new US GLP-1 prescriptions; Novo tightened its full-year guidance to a 4-12% sales decline (from 5-13%). The international expansion is the inflection point for Novo's competitive positioning vs Lilly's Foundayo and the next-generation Mounjaro/Zepbound franchise.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.